{"id":"ceacam5","name":"CEACAM5","symbol":"CEACAM5","route":"/targets/ceacam5/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1817","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105388","uniprot":"https://www.uniprot.org/uniprotkb/P06731/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P06731","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712881","open-targets":"https://platform.opentargets.org/target/ENSG00000105388","civic":"https://civicdb.org/genes/1048/summary","oncokb":"https://www.oncokb.org/gene/CEACAM5","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CEACAM5","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CEACAM5","depmap":"https://depmap.org/portal/gene/CEACAM5?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000105388-CEACAM5","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1048","omim":"https://www.omim.org/entry/114890"}],"products":[{"id":"ose2101","name":"OSE2101","status":"phase-3","modality":"vaccine","route":"/drugs/ose2101/"},{"id":"precemtabart-tocentecan","name":"Precemtabart tocentecan","status":"phase-3","modality":"ADC","route":"/drugs/precemtabart-tocentecan/"},{"id":"sgm-101","name":"SGM-101","status":"phase-3","modality":"monoclonal antibody","route":"/drugs/sgm-101/"},{"id":"tusamitamab-ravtansine","name":"Tusamitamab ravtansine","status":"withdrawn","modality":"ADC","route":"/drugs/tusamitamab-ravtansine/"}],"trials":[{"id":"nct04154956","name":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","nct":"NCT04154956","phase":"3"},{"id":"proceade-crc-03","name":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","nct":"NCT07549412","phase":"3","status":"recruiting"},{"id":"nct03659448","name":"Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer","nct":"NCT03659448","phase":"3","status":"recruiting"},{"id":"nct06472245","name":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","nct":"NCT06472245","phase":"3","status":"recruiting"},{"id":"nct04524689","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","nct":"NCT04524689","phase":"2"},{"id":"nct04659603","name":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors","nct":"NCT04659603","phase":"2"},{"id":"nct05751798","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","nct":"NCT05751798","phase":"1/2","status":"recruiting"},{"id":"nct07462650","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","nct":"NCT07462650","phase":"1/2","status":"recruiting"},{"id":"nct07589517","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","nct":"NCT07589517","phase":"1/2","status":"recruiting"},{"id":"nct06710132","name":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","nct":"NCT06710132","phase":"1/2","status":"active"}],"pathways":[],"companies":["merck-kgaa","ose-immunotherapeutics","sanofi","surgimab"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}